Gimv participates in a $92M Series A financing round at Kivu Bioscience to advance next-gen antibody-drug conjugates

28 Oct 2024 17:45 CET

Issuer

GIMV

See attachment(s) / Voir document(s) joint(s) / Zie bijlage / Ver documento(s) em anexo

16165_1293243_241028_PR_Kivu_BioScience_EN.pdf

Source

Gimv

Provider

Les Echos

Company Name

GIMV

ISIN

BE0003699130

Symbol

GIMB

Market

Euronext